Company intelligence / Profile preview

HC2 Holdings

New York, New York, United States

Ownership: Private
Employees: ~2848
Development stage: Other

Overview

HC2 Holdings is a diversified holding company with activities in life sciences centered on Pansend Life Sciences. Pansend and its subsidiaries/portfolio companies have advanced medical devices and biotechnologies to clinical/commercial stage, including an FDA-cleared dermatology device and kidney function diagnostics. HC2 previously owned BeneVir, which developed oncolytic immunotherapies for cancer and was acquired by Johnson & Johnson for up to $1.04B.

Industry: Investors

Partnerships

Huadong Medicine Company Limited (strategic investment and distribution for R2 Technologies)

Beyond the preview

Go deeper on HC2 Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HC2 Holdings.

Explore the full profile